Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia
Advanced Science · 2024
DOI: 10.1002/advs.202307022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yingying Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, The Second Affiliated Hospital, Institute of Translational Medicine, School of Public Health, State Key Laboratory of …. Hauptthemen laut MEDLINE: Anemia, Anemia, Refractory. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
In clinics, hepcidin levels are elevated in various anemia‐related conditions, particularly in iron‐refractory anemia and in high inflammatory states that suppress iron absorption, which remains an urgent unmet medical need. To identify effective treatment options for various types of iron‐refractory anemia, the potential effect of hypoxia and pharmacologically‐mimetic drug FG‐4592 (Roxadustat) are evaluated, a hypoxia‐inducible factor (HIF)‐prolyl hydroxylase (PHD) inhibitor, on mouse models of iron‐refractory iron‐deficiency anemia (IRIDA), anemia of inflammation and 5‐fluorouracil‐induced chemotherapy‐related anemia. The potent protective effects of both hypoxia and FG‐4592 on IRIDA as well as other 2 tested mouse cohorts are found. Mechanistically, it is demonstrated that hypoxia or FG‐4592 could stabilize duodenal Hif2α, leading to the activation of Fpn transcription regardless of hepcidin levels, which in turn results in increased intestinal iron absorption and the amelioration of hepcidin‐activated anemias. Moreover, duodenal Hif2α overexpression fully rescues phenotypes of Tmprss6 knockout mice, and Hif2α knockout in the gut significantly delays the recovery from 5‐fluorouracil‐induced anemia, which can not be rescued by FG‐4592 treatment. Taken together, the findings of this study provide compelling evidence that targeting intestinal hypoxia‐related pathways can serve as a potential therapeutic strategy for treating a broad spectrum of anemia, especially iron refractory anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, The Second Affiliated Hospital, Institute of Translational Medicine, School of Public Health, State Key Laboratory of Experimental Hematology, Zhejiang University School of Medicine, Hangz…
- The First Affiliated Hospital, Basic Medical Sciences, School of Public Health, Hengyang Medical School, University of South China, Hengyang, 421001, China.
- Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, 48109, USA.
- Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
- International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, Zhejiang, China.
ORCID-Profile: Yingying Yu, Yunxing Su, Junxia Min, Fudi Wang
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIH HHS
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Institutes of Health
Zitieren
APA
Yu, Y., Su, Y., Yang, S., Liu, Y., Lin, Z., Das, N. K., Wu, Q., Zhou, J., Sun, S., Li, X., Yue, W., Shah, Y. M., Min, J., & Wang, F. (2024). Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia. Advanced Science. https://doi.org/10.1002/advs.202307022
Vancouver
Yu Y, Su Y, Yang S, Liu Y, Lin Z, Das NK, et al. Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia. Advanced Science. 2024. doi:10.1002/advs.202307022
BibTeX
@article{Yu2024,
author = {Yu, Yingying and Su, Yunxing and Yang, Sisi and Liu, Yutong and Lin, Zhiting and Das, Nupur K and Wu, Qian and Zhou, Jiahui and Sun, Shumin and Li, Xiaopeng and Yue, Wuyang and Shah, Yatrik M and Min, Junxia and Wang, Fudi},
title = {Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202307022}
}
EUVIMED